comparemela.com

Page 3 - Obstruction Impact News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Positive Topline Results for SEQUOIA-HCM Trial in OHCM

Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.

United statesFadyi malikMartins maronTufts university school of medicineDrug administrationResearch developmentNational principal investigatorNational medical products administrationHypertrophic cardiomyopathy centerQuantitative understandingObstruction impactLahey hospitalMedical centerTufts university schoolCytokinetic executive vice presidentPatients with

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy -December 27, 2023 at 07:31 am EST

Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant.

United statesFadyi malikDiane weiserMartin maronTufts university school of medicineExchange commissionUs food drug administrationGlobenewswire incCytokinetics incorporated nasdaqNational medical products administrationCytokinetics incorporatedCorporate communicationsResearch developmentSymphony healthClinical trials programHypertrophic cardiomyopathy center

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

27.12.2023 - Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant and Clinically Meaningful Improvements in All . Seite 1

Cytokinetics incorporated nasdaqCompany to host conference callTreatment interruptions dueHost conference callWebcast todayQuantitative understandingObstruction impactCytokinetics chartYtokinetics kursYtokinetics aktie

Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients…

SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) Cytokinetics, Incorporated CYTK today announced that members of its senior management will host…

Cytokinetics incorporatedQuantitative understandingObstruction impactReaking news

Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from

SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of its senior management will host an investor call at 8:30 AM

United statesDiane weiserJournal of the american college cardiologySymphony healthCorporate communicationsCytokinetics incorporated nasdaqExchange commissionQuantitative understandingObstruction impactTopline resultsPrivate securities litigation reform actSafe harborVice presidentHeart failureClaims data dofClinically diagnosed hypertrophic cardiomyopathy

vimarsana © 2020. All Rights Reserved.